Bristol-Myers Squibb Co.

NYSE:BMY   3:59:57 PM EDT
+0.22 (+0.38%)

U.S. FDA Accepts For Priority Review Bristol Myers Squibb's Application For Lag-3-Blocking Antibody Relatlimab And Nivolumab Fixed-Dose Combination

Published: 09/20/2021 11:17 GMT
Bristol-Myers Squibb Co. (BMY) - U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Lag-3-blocking Antibody Relatlimab and Nivolumab Fixed-dose Combination As Treatment for Patients With Unresectable Or Metastatic Melanoma.
Bristol-myers Squibb Co - U.S. Food and Drug Administration Assigns a Target Action Date of March 19, 2022.